Skip to main content
Premium Trial:

Request an Annual Quote

Kymera Therapeutics Begins Phase I Trial in MYD88-Mutant Lymphoma

NEW YORK – Kymera Therapeutics said on Wednesday it has dosed the first patient in a Phase I study of its protein degrader KT-413 in MYD88-mutant diffuse large B cell lymphoma.

The trial will enroll 80 patients with relapsed or refractory B-cell non-Hodgkin lymphomas to evaluate single-agent KT-413. In the initial stage of the study, researchers will enroll patients with diffuse large B cell lymphoma with or without MYC and BCL2 or BCL6 rearrangements, Epstein-Barr virus-positive DLBCL, and human herpesvirus 8 (HHV8)-positive DLBCL. In the Phase Ib portion of the study, researchers will evaluate the drug in both MYD88-mutant and MYD88 wild-type diffuse large B cell lymphoma.

KT-413, an IRAKIMiD degrader, can target both the MYD88-NFkB and IRF4-Type 1 interferon pathways to promote anti-tumor activity. Kymera may also expand the KT-413 program into other MYD88-mutant indications and IL-1R- or NFkB-driven malignancies.

Initial safety and proof-of-mechanism data from the trial will be reported in the second half of 2022, the company said.

On Wednesday, Kymera also announced it has dosed the first patient in a separate study of its STAT3 degrader, KT-333, which is being explored in an all-comer population in both liquid and solid tumors. The firm's preclinical data showed KT-333 could degrade both mutant and wild-type STAT3.

Watertown, Massachusetts-based Kymera is also developing an MDM2 degrader that is in preclinical studies, with an investigational new drug submission expected in the second half of 2022.